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compared to HAQ-DI (0.004 improvement in utility per unit decrease in PASI). Using 
these algorithms, the incremental cost-effectiveness ratios (ICER) were calculated 
for each biologic versus standard of care. For each biologic ICERs coefficient of vari-
ation (standard deviation/mean) was approx. 17%. ConClusions: HAQ-DI is the 
key influencing variable in deriving utility values for PsA patients in the current 
algorithms. In biologic cost-effectiveness models, ICER is sensitive to the algorithms 
used. The analysis suggests that there may be a need of an improved algorithm to 
inform cost-effectiveness models for predicting utility more accurately. This may 
help the healthcare decision makers to make more informed decisions.
PMS110
The ASSociATion beTween DiSeASe AcTiviTy AnD QuAliTy of life 
AMong PATienTS wiTh AnkyloSing SPonDyliTiS in PoliSh PoPulATion
Malinowski K, Kawalec P
Jagiellonian University Medical Collage Institute of Public Health, Krakow, Poland
objeCtives: The aim of this study was to assess the disease activity and quality of 
life of patients with ankylosing spondylitis (AS) in Polish population. Methods: 
On-line questionnaire survey was performed to obtain data on disease activity 
and the quality of life. We used Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and EQ-5D questionnaires with visual analogue scale (VAS). BASDAI score 
was obtained using on-line calculator. EQ-5D states were converted into utilities for 
European population. The Spearman’s correlation was used to present the associa-
tion between the disease activity and the quality of life. Results: A total number of 
66 questionnaires was obtained. Patients reported mostly the problems with general 
discomfort and morning stiffness represented by 8 points on BASDAI scale, followed 
by tiredness and neck pain represented by 7 points and other pain represented by 5 
points. Almost 30% of patients reported that morning stiffness lasts longer than two 
hours. The mean BASDAI score was 5.87 (SD: 1.81). Of all patients, 68% reported some 
(highest reported state) problems with mobility, 47% with looking after himself. A lot 
(highest reported state) of problems with usual activities reported 4% of patients, a 
lot of pain and discomfort was reported by 13% of patients and with feeling worried 
by 6%. In all domains “some problems” was the most frequent answer resulting that 
the most common EQ-5D state was “22222”. The mean utility was 0.52 (SD: 0.195) 
varied from 0 to 1. Patient reported visual analogue scale was 47 (SD: 26) varied 
from 0 to 100. BASDAI score was significantly correlated with utility (-0.635) and VAS 
(-0.620). ConClusions: Ankylosing spondylitis significantly reduces the quality of 
life. The higher the BASDAI score representing the higher disease activity and the 
lower the quality of life, reported as both EQ-5D utility and VAS.
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objeCtives: Non-radiographic axial spondyloarthritis (nr-axSpA) is an inflammatory 
arthritic disease characterized by sacroiliac joint inflammation. Studies indicate that 
nr-axSpA is a long-term chronic condition and can impose a considerable burden on 
the patients’ physical function, impairment, and health-related quality of life. This 
analysis aimed to investigate whether elements of the burden associated with nr-
axSpA are avoidable. Methods: Data were from the 2014 nr-axSpA Disease Specific 
Programme, a cross-sectional, multi-national survey of patients and rheumatolo-
gists conducted in France, Germany, Italy, Spain and the UK. Rheumatologists com-
pleted forms containing patient demographics, clinical results and symptomology. 
Patients completed patient self-completions (PSCs) containing the Work Productivity 
and Activity Impairment questionnaire and EuroQoL-5D (EQ-5D-3L) with the visual 
analogue scale (EQ-VAS). Biologic treatment naïve patients considered eligible for bio-
logics by the physician were compared to patients receiving biologics for ≥ 6 months. 
Observations were weighted to ensure findings were more representative of the 
patient population. The weight was applied to all percentages, means and standard 
deviations (SDs). Appropriate weighted univariate regressions were performed to 
test for significance. Results: The analysis comprised of 310 patients (mean age 
42.5±11.8 [SD], 74.8% male), with 123 biologic-naïve and 187 biologic-treated patients. 
Only 76 PSCs were completed in total. Compared to biologic-treated patients, biologic-
naïve patients had greater overall work impairment (37.1% vs. 18.8%), presentee-
ism (27.6% vs. 15.8%) and activity impairment (31.4% vs. 22.5%). Additionally, more 
biologic-naïve patients were currently experiencing acute episodes (12.7% vs. 2.5%) 
and inflammatory back pain (69.5% vs. 38.5%) (all p< 0.05). There were no observed 
differences between cohorts regarding mean EQ-5D utility score (0.81 vs. 0.82) or 
EQ-VAS (65.5 vs. 64.8). ConClusions: A potential unmet has been highlighted in 
nr-axSpA patient management, which could be due to restrictions upon physicians 
prescribing choices. Reducing the duration between diagnosis and biologic treatment 
prescription could potentially lessen the societal and clinical burden of nr-axSpA.
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objeCtives: To describe residual skin and joint disease and health-related qual-
ity of life (HRQoL) in psoriatic arthritis (PsA) patients treated with biologics, and 
explore the impact of residual disease on HRQoL, work productivity, and switching 
therapies. Methods: This was a retrospective analysis of 2013/14 US-EU5 Adelphi 
Real World cross-sectional survey data from dermatologists, rheumatologists, and 
PsA patients receiving biologics for ≥ 6-months. Outcomes included: EuroQol-5 
Dimension (EQ-5D), Health Assessment Questionnaire Disability Index (HAQ-DI) 
(rheumatologists), PROMIS-HAQ) (dermatologists), Dermatology Life Quality Index 
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objeCtives: To determine which patient-reported outcome (PRO) tools were 
used in studies on musculoskeletal diseases published in 2014. Methods: An 
evidence surveillance process was established based on a systematic search 
of PubMed, incorporating all studies published from 2010 and updated weekly, 
with a final search on 18 May 2015. Abstracts identified by the search that 
reported quality of life outcomes in musculoskeletal disorders were identified. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified from the 
abstract alone, where possible. Results: The search identified 1,980 articles 
published in 2014. Of these, 197 (10%) were in musculoskeletal disorders. The 
most commonly researched diseases were osteoarthritis (19 articles), rheu-
matoid arthritis and back pain (14 each), fibromyalgia and fractures (10 each), 
and ankylosing spondylitis (9). Overall, 160 different PRO or clinician-reported 
instruments were cited in the 197 abstracts, with 93 articles citing more than 
one tool. Pain instruments were most commonly used (82 articles included 
either VAS or unspecified pain measurement). Utility measurement was made 
in 36 studies, with SF-36 used twice as often as either SF-12 or EQ-5D. PROs most 
commonly cited included WOMAC (13 articles), DASH (9), KOOS (9), HAQ (8), 
WHOQOL-BREF (6), FIQ and WOSI (5 each). The PRO used was not specified in 52 
article abstracts: 22 of the 143 primary research articles, 7 of 18 study protocols 
and 30 of 34 systematic reviews. ConClusions: A wide range of musculoskel-
etal disorders were researched in 2014, with little overlap in PRO tools used 
even within diseases. Standardisation of tool use would aid comparison of out-
comes across studies. Evidence surveillance including study protocols, results 
and systematic reviews may help identify trends in PRO use within specific 
diseases.
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objeCtives: Fibromyalgia is a chronic pain syndrome characterized by increased 
sensitivity to pain, fatigue, muscle stiffness, difficulty sleeping, problems with 
mental processes (known as “fibro-fog”), such as problems with memory and con-
centration, headaches, and irritable bowel syndrome. The objectives of this study 
were 1) to identify patient-reported outcome (PRO) claims in products specifically 
approved for the treatment of fibromyalgia by the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) since 1995, and 2) to identify 
the endpoint positioning of the PROs when measured. Methods: The websites 
of the FDA and the EMA were explored to identify all products approved specifi-
cally for fibromyalgia. PROLabels was used to identify products with a PRO claim 
in label. All corresponding clinical reviews (FDA), and assessments reports (EMA) 
were reviewed to check for endpoint positioning. Results: Since 1995, only three 
products have been approved with the specific indication of fibromyalgia (three by 
the FDA, i.e., duloxetine, milnacipran and pregabalin). None have been approved by 
the EMA. All of the products approved by the FDA include PRO claims in their label: 
reduction in pain, improvements in function, and in patient global impression of 
change (PGIC). When the medical review was available (duloxetine, milnacipran), 
the analysis of endpoint positioning showed that reduction in pain (either meas-
ured by the overall score of the Brief Pain Inventory or a Visual Analog Scale) was 
the primary efficacy endpoint. In one case (duloxetine), and for one study, the PGIC 
was also considered as a primary endpoint. Function was a secondary endpoint 
measured either by the Fibromyalgia Impact Questionnaire (duloxetine, pregaba-
lin) or the SF-36 Physical Component Summary (milnacipran). ConClusions: 
PROs are essential to the evaluation of fibromyalgia products and are included in 
the labels of all products approved by the FDA. Reduction in pain is the key primary 
endpoint.
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objeCtives: To evaluate the relationship between the disease activity measures 
(HAQ, PASI) and patient’s QoL based on different utility mappings and its influ-
ence on cost-effectiveness (CE) Methods: The identified algorithms of a litera-
ture research project that includes database screening of publications in English 
language from 1996-2015 have been extracted and the differences have been 
explored in a CE model for PsA. The model follows a decision tree for the first 12 
weeks and Markov structure for rest of the time horizon with three month cycle 
length. Results: The research retrieved 13 different algorithms to derive utilities in 
PsA patients based on clinical study data. In these studies, utilities were measured 
either with the SF-36 (n= 5) or the EQ-5D (n= 9) instruments. Different algorithms 
used different independent variables such as HAQ-DI, PASI or Disease Activity Score 
28 (DAS28) to predict utility values. The arthritis component of the disease was 
measured either through HAQ-DI (n= 11) or DAS28 (n= 2), whereas PASI was used 
for the skin component (n= 4). Most of the algorithms were using a linear approach 
(n= 11). Among these linear algorithms one unit decrease of HAQ-DI improves 
patient’s utility by 0.1 to 0.3 units. Effect of PASI on utility was much smaller as 
